journal
MENU ▼
Read by QxMD icon Read
search

Oncolytic Virotherapy

journal
https://www.readbyqxmd.com/read/29765912/oncolytic-adenovirus-ad657-for-systemic-virotherapy-against-prostate-cancer
#1
Tien V Nguyen, Catherine M Crosby, Gregory J Heller, Zachary I Mendel, Mary E Barry, Michael A Barry
Background: Human species C adenovirus serotype 5 (Ad5) is the archetype oncolytic adenovirus and has been used in the vast majority of preclinical and clinical tests. While Ad5 can be robust, species C Ad6 has lower seroprevalence, side effects, and appears to be more potent as a systemic therapy against a number of tumors than Ad5. Historically, there have only been four species C human adenoviruses: serotypes 1, 2, 5, and 6. More recently a new species C adenovirus, Ad57, was identified...
2018: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/29750140/proof-of-principle-that-a-decoy-virus-protects-oncolytic-measles-virus-against-neutralizing-antibodies
#2
Chun Xu, Annika Verena Goß, Carmen Dorneburg, Klaus-Michael Debatin, Jiwu Wei, Christian Beltinger
Background: Attenuated oncolytic measles virus (OMV) is a promising antitumor agent in early-phase clinical trials. However, pre-existing immunity against measles might be a hurdle for OMV therapy. Methods: OMV was inactivated with short-wavelength ultraviolet light (UV-C). Loss of replication and oncolytic activity of UV-inactivated OMV were confirmed by tissue culture infective dose 50 (TCID50 ) assay using Vero cells and by flow cytometry using Jurkat cells. An enzyme-linked immunosorbent assay was performed to verify that UV-inactivated OMV remained antigenic...
2018: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/29637059/the-importance-of-imaging-strategies-for-pre-clinical-and-clinical-in-vivo-distribution-of-oncolytic-viruses
#3
REVIEW
Adrian Pelin, Jiahu Wang, John Bell, Fabrice Le Boeuf
Oncolytic viruses (OVs) are an emergent and unique therapy for cancer patients. Similar to chemo- and radiation therapy, OV can lyse (kill) cancer cell directly. In general, the advantages of OVs over other treatments are primarily: a higher safety profile (as shown by less adverse effects), ability to replicate, transgene(s) delivery, and stimulation of a host's immune system against cancer. The latter has prompted successful use of OVs with other immunotherapeutic strategies in a synergistic manner. In spite of extended testing in pre-clinical and clinical setting, using biologically derived therapeutics like virus always raises potential concerns about safety (replication at non-intended locations) and bio-availability of the product...
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/29616200/oncolytic-virotherapy-in-upper-gastrointestinal-tract-cancers
#4
REVIEW
Raquel Yokoda, Bolni M Nagalo, Mansi Arora, Jan B Egan, James M Bogenberger, Thomas T DeLeon, Yumei Zhou, Daniel H Ahn, Mitesh J Borad
Upper gastrointestinal tract malignancies are among the most challenging cancers with regard to response to treatment and prognosis. Cancers of the esophagus, stomach, pancreas, liver, and biliary tree have dismal 5-year survival, and very modest improvements in this rate have been made in recent times. Oncolytic viruses are being developed to address these malignancies, with a focus on high safety profiles and low off-target toxicities. Each viral platform has evolved to enhance oncolytic potency and the clinical response to either single-agent viral therapy or combined viral treatment with radiotherapy and chemotherapy...
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/29503813/potential-of-oncolytic-viruses-in-the-treatment-of-multiple-myeloma
#5
REVIEW
Eric Bartee
Multiple myeloma (MM) is a clonal malignancy of plasma cells that is newly diagnosed in ~30,000 patients in the US each year. While recently developed therapies have improved the prognosis for MM patients, relapse rates remain unacceptably high. To overcome this challenge, researchers have begun to investigate the therapeutic potential of oncolytic viruses as a novel treatment option for MM. Preclinical work with these viruses has demonstrated that their infection can be highly specific for MM cells and results in impressive therapeutic efficacy in a variety of preclinical models...
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/29184854/oncolytic-virus-delivery-from-nano-pharmacodynamics-to-enhanced-oncolytic-effect
#6
REVIEW
Raquel Yokoda, Bolni M Nagalo, Brent Vernon, Rahmi Oklu, Hassan Albadawi, Thomas T DeLeon, Yumei Zhou, Jan B Egan, Dan G Duda, Mitesh J Borad
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticles, immunomodulatory agents and complex viral-particle ligands along with manipulations of the tumor microenvironment...
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/28331843/curative-effect-of-hf10-on-liver-and-peritoneal-metastasis-mediated-by-host-antitumor-immunity
#7
Yoshihiro Hotta, Hideki Kasuya, Itzel Bustos, Yoshinori Naoe, Toru Ichinose, Maki Tanaka, Yasuhiro Kodera
BACKGROUND: HF10 is a highly attenuated type 1 herpes simplex virus (HSV) with proven effective oncolytic effect. Previous investigations have demonstrated that colon cancer mice model treated with HF10 not only had better survival but were also resistant to the reimplantation of the antitumor effect mediated by host antitumor immunity. Importantly, it has also been noted that in mice with antitumors implanted on both sides of the back, an injection of HF10 on only one side strongly restrains not only the injected antitumor but also the non-injected ones...
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/28293547/proinflammatory-response-induced-by-newcastle-disease-virus-in-tumor-and-normal-cells
#8
Teridah Ernala Ginting, Jeremiah Suryatenggara, Salomo Christian, George Mathew
PURPOSE: To investigate the specific role of immune responses induced by lentogenic Newcastle disease virus (NDV) for its antitumor effect. MATERIALS AND METHODS: NDV LaSota strain was used to infect the following human cells: non-small cell lung carcinoma (A549), glioblastoma (U87MG and T98G), mammary gland adenocarcinoma (MCF7 and MDA-MB-453), hepatocellular carcinoma (Huh7), transformed embryonic kidney cells (HEK293), primary monocytes, lung fibroblast (HF19), skin fibroblast (NB1RGB) and rat astroglia (RCR-1) at 0...
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/28243580/editorial-announcing-pubmed-indexing-of-oncolytic-virotherapy
#9
EDITORIAL
Faris Farassati
No abstract text is available yet for this article.
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/28224120/oncolytic-virotherapy-including-rigvir-and-standard-therapies-in-malignant-melanoma
#10
REVIEW
Hani M Babiker, Irbaz Bin Riaz, Muhammad Husnain, Mitesh J Borad
The treatment of metastatic melanoma has evolved from an era where interferon and chemotherapy were the mainstay of treatments to an era where immunotherapy has become the frontline. Ipilimumab (IgG1 CTLA-4 inhibitor), nivolumab (IgG4 PD-1 inhibitor), pembrolizumab (IgG4 PD-1 inhibitor) and nivolumab combined with ipilimumab have become first-line therapies in patients with metastatic melanoma. In addition, the high prevalence of BRAF mutations in melanoma has led to the discovery and approval of targeted molecules, such as vemurafenib (BRAF kinase inhibitor) and trametinib (MEK inhibitor), as they yielded improved responses and survival in malignant melanoma patients...
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/28053943/novel-oncolytic-viral-therapies-in-patients-with-thoracic-malignancies
#11
REVIEW
Zeeshan Ahmad, Robert A Kratzke
Oncolytic virotherapy is the use of replication-competent viruses to treat malignancies. The potential of oncolytic virotherapy as an approach to cancer therapy is based on historical evidence that certain viral infections can cause spontaneous remission of both hematologic and solid tumor malignancies. Oncolytic virotherapy may eliminate cancer cells through either direct oncolysis of infected tumor cells or indirect immune-mediated oncolysis of uninfected tumor cells. Recent advances in oncolytic virotherapy include the development of a wide variety of genetically attenuated RNA viruses with precise cellular tropism and the identification of cell-surface receptors that facilitate viral transfer to the tissue of interest...
2017: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27957479/cxcl12-retargeting-of-an-adenovirus-vector-to-cancer-cells-using-a-bispecific-adapter
#12
Shilpa Bhatia, Samia M O'Bryan, Angel A Rivera, David T Curiel, J Michael Mathis
Ad vectors are promising delivery vehicles for cancer therapeutic interventions. However, their application is limited by promiscuous tissue tropism and hepatotoxicity. This limitation can be avoided by altering the native tropism of Ads so that they can be redirected to the target cells through alternate cellular receptors. The CXCR4 chemokine receptor belongs to a large superfamily of G-protein-coupled receptors and is known to be upregulated in a wide variety of cancers, including breast cancer and melanoma...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27785448/spotlight-on-talimogene-laherparepvec-for-the-treatment-of-melanoma-lesions-in-the-skin-and-lymph-nodes
#13
REVIEW
Marlana Orloff
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added yet another therapeutic option to the growing list of effective therapies for melanoma. Though the Phase III OPTiM trial has demonstrated its efficacy as a single agent, the target patient population remains narrow. With numerous effective and tolerable treatments available for unresectable and metastatic melanoma, intralesional therapies such as T-VEC are still finding their niche...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27660749/oncolytic-seneca-valley-virus-past-perspectives-and-future-directions
#14
REVIEW
Michael J Burke
Seneca Valley Virus isolate 001 (SVV-001) is an oncolytic RNA virus of the Picornaviridae family. It is also the first picornavirus discovered of the novel genus Senecavirus. SVV-001 replicates through an RNA intermediate, bypassing a DNA phase, and is unable to integrate into the host genome. SVV-001 was originally discovered as a contaminant in the cell culture of fetal retinoblasts and has since been identified as a potent oncolytic virus against tumors of neuroendocrine origin. SVV-001 has a number of features that make it an attractive oncolytic virus, namely, its ability to target and penetrate solid tumors via intravenous administration, inability for insertional mutagenesis, and being a self-replicating RNA virus with selective tropism for cancer cells...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27579298/oncolytic-virotherapy-for-pediatric-malignancies-future-prospects
#15
REVIEW
Alicia M Waters, Gregory K Friedman, Eric K Ring, Elizabeth A Beierle
Pediatric solid tumors remain a major health concern, with nearly 16,000 children diagnosed each year. Of those, ~2,000 succumb to their disease, and survivors often suffer from lifelong disability secondary to toxic effects of current treatments. Countless multimodality treatment regimens are being explored to make advances against this deadly disease. One targeted treatment approach is oncolytic virotherapy. Conditionally replicating viruses can infect tumor cells while leaving normal cells unharmed. Four viruses have been advanced to pediatric clinical trials, including herpes simplex virus-1, Seneca Valley virus, reovirus, and vaccinia virus...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27579297/myxoma-virus-therapy-for-human-embryonal-rhabdomyosarcoma-in-a-nude-mouse-model
#16
Veronica G Kinn, Valerie A Hilgenberg, Amy L MacNeill
Rhabdomyosarcoma (RMS) is a devastating tumor of young people that is difficult to cure. To determine if oncolytic virus therapy can improve outcomes in individuals with RMS, myxoma virus expressing a red fluorescent protein (MYXV-red) was evaluated for antitumoral effects using a murine model of RMS. Fluorescent protein was expressed in four RMS cell lines inoculated with MYXV-red, indicating that these cells were semipermissive to MYXV infection. MYXV-red replication and cytopathic effects were further evaluated using human embryonal RMS (CCL-136) cells...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27579296/oncolytic-adenovirus-mediated-therapy-for-prostate-cancer
#17
REVIEW
Katrina Sweeney, Gunnel Halldén
Prostate cancer is a leading cause of cancer-related death and morbidity in men in the Western world. Tumor progression is dependent on functioning androgen receptor signaling, and initial administration of antiandrogens and hormone therapy (androgen-deprivation therapy) prevent growth and spread. Tumors frequently develop escape mechanisms to androgen-deprivation therapy and progress to castration-resistant late-stage metastatic disease that, in turn, inevitably leads to resistance to all current therapeutics, including chemotherapy...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27579295/thyroid-malignant-neoplasm-associated-biomarkers-as-targets-for-oncolytic-virotherapy
#18
REVIEW
Mingxu Guan, Yanping Ma, Sahil Rajesh Shah, Gaetano Romano
Biomarkers associated with thyroid malignant neoplasm (TMN) have been widely applied in clinical diagnosis and in research oncological programs. The identification of novel TMN biomarkers has greatly improved the efficacy of clinical diagnosis. A more accurate diagnosis may lead to better clinical outcomes and effective treatments. However, the major deficiency of conventional chemotherapy and radiotherapy is lack of specificity. Due to the macrokinetic interactions, adverse side effects will occur, including chemotherapy and radiotherapy resistance...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27579294/newcastle-disease-virus-rituximab-and-doxorubicin-combination-as-anti-hematological-malignancy-therapy
#19
Ahmed Majeed Al-Shammari, Huda Rameez, Maha F Al-Taee
Hematological malignancies are important diseases that need more powerful therapeutics. Even with current targeting therapies, such as rituximab and other chemotherapeutic agents, there is a need to develop new treatment strategies. Combination therapy seems the best option to target the tumor cells by different mechanisms. Virotherapy is a very promising treatment modality, as it is selective, safe, and causes cancer destruction. The Iraqi strain of Newcastle disease virus (NDV) has proved to be effective both in vitro and in vivo...
2016: Oncolytic Virotherapy
https://www.readbyqxmd.com/read/27579293/high-throughput-screening-to-enhance-oncolytic-virus-immunotherapy
#20
REVIEW
K J Allan, David F Stojdl, S L Swift
High-throughput screens can rapidly scan and capture large amounts of information across multiple biological parameters. Although many screens have been designed to uncover potential new therapeutic targets capable of crippling viruses that cause disease, there have been relatively few directed at improving the efficacy of viruses that are used to treat disease. Oncolytic viruses (OVs) are biotherapeutic agents with an inherent specificity for treating malignant disease. Certain OV platforms - including those based on herpes simplex virus, reovirus, and vaccinia virus - have shown success against solid tumors in advanced clinical trials...
2016: Oncolytic Virotherapy
journal
journal
48876
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"